Per Källblad, Ph.D.
Per Källblad co-founded Beactica in 2006 and is Chief Executive Officer. He has significant international experience in interdisciplinary pharmaceutical research and has worked in collaborations with Aventis, Rhone-Poulenc Rorer, Roche, Cancer Research UK, Peakdale Molecular, Biovitrum and Tibotec.
Per received his Ph.D. in Drug Design from Cambridge University, UK. He was a founding scientist at De Novo Pharmaceuticals Ltd (1999-2004), a Cambridge University spin-off that raised £17.5m in venture capital to bring a new drug discovery tool to market. At Medivir AB he worked with preclinical strategies for therapeutic targets on internal and external projects (2004-2006).
Helena Danielson, Prof.
Helena Danielson co-founded Beactica in 2006 and is Chief Scientific Officer. She is a specialist in enzyme-based drug discovery and has adapted biosensor technology for detailed studies of enzyme-inhibitor interactions. She has profound experience of the commercial drug discovery process through more than 15 years of collaborative research with industrial partners.
At the Karolinska Institute she initiated a research project on HIV protease as a drug target for AIDS. In 1987 this work lead to a collaboration with Medivir AB that has been ongoing since. Her longstanding work with Biacore AB has resulted in the development of new biosensor products of wide use in the discovery industry. She is Professor of Biochemistry at Uppsala University since 2002.
Evert Homan, Ph.D.
Evert Homan joined Beactica in 2008 and is Chief Operations Officer. He has more than ten years experience from the international pharmaceutical industry and a broad knowledge of the preclinical small-molecule drug discovery process.
Evert holds an M.Sc. in Pharmacy (1993) and a Ph.D. (1998) in Medicinal Chemistry from Groningen University, the Netherlands. He worked at Pharmacopeia, Inc., Princeton, NJ (1999–2000), before joining Pharmacia in Stockholm, Sweden (2000–2001). From 2001 until joining Beactica, he worked at Biovitrum where he was involved in over a dozen early drug discovery projects. During this period he also worked as chemistry team leader for lead generation projects and was involved in defining new disease area strategies as well as target identification.
